Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Recruiting1
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

recruiting133%
withdrawn133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
withdrawnphase_2

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

NCT06765954
recruitingphase_2

A Study to Assess Anktiva in Patients With Long Covid-19.

NCT07108036
active_not_recruitingphase_1

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

NCT04340596

Clinical Trials (3)

Showing 3 of 3 trials
NCT06765954Phase 2

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Withdrawn
NCT07108036Phase 2

A Study to Assess Anktiva in Patients With Long Covid-19.

Recruiting
NCT04340596Phase 1

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active Not Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3